Search

Your search keyword '"Ansell, S.M."' showing total 133 results
Start Over Author "Ansell, S.M."
133 results on '"Ansell, S.M."'

1. The Role of Radiation Therapy in the Management of Gray Zone Lymphoma

Author

Saifi, O., primary, Rule, W.G., additional, Lester, S.C., additional, Laack, N.N., additional, Breen, W., additional, Rosenthal, A., additional, Ansell, S.M., additional, Habermann, T.M., additional, Villasboas Bisneto, J., additional, Iqbal, M., additional, Alhaj Moustafa, M., additional, Tun, H., additional, Kharfan-Dabaja, M., additional, Peterson, J.L., additional, and Hoppe, B.S., additional

Published
2023
Full Text
View/download PDF

2. Consolidative Radiotherapy for Residual PET-Avid Disease on Day +30 Post CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Author

Saifi, O., primary, Lester, S.C., additional, Rule, W.G., additional, Breen, W., additional, Stish, B.J., additional, Rosenthal, A., additional, Munoz, J., additional, Lin, Y., additional, Johnston, P., additional, Ansell, S.M., additional, Paludo, J., additional, Khurana, A., additional, Bisneto, J. Villasboas, additional, Wang, Y., additional, Iqbal, M., additional, Moustafa, M. Alhaj, additional, Murthy, H.S., additional, Kharfan-Dabaja, M., additional, Peterson, J.L., additional, and Hoppe, B.S., additional

Published
2023
Full Text
View/download PDF

3. The Impact of Radiation Timing in Peri-CAR T-Cell Therapy on Local Control for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Author

Saifi, O., primary, Breen, W., additional, Lester, S.C., additional, Rule, W.G., additional, Stish, B.J., additional, Rosenthal, A., additional, Munoz, J., additional, Lin, Y., additional, Bennani, N., additional, Paludo, J., additional, Khurana, A., additional, Bisneto, J. Villasboas, additional, Johnston, P., additional, Ansell, S.M., additional, Iqbal, M., additional, Moustafa, M. Alhaj, additional, Murthy, H.S., additional, Kharfan-Dabaja, M., additional, Hoppe, B.S., additional, and Peterson, J.L., additional

Published
2022
Full Text
View/download PDF

4. Patterns of Progression on Immune Checkpoint Inhibitor Therapy for Relapsed Hodgkin Lymphoma: Implications for the Potential Role of Radiation Therapy

Author

Burlile, J.F., primary, Breen, W., additional, Hwang, S.R., additional, Higgins, A.S., additional, Nedved, A.N., additional, Harmsen, W.S., additional, Witzig, T., additional, Micallef, I.N., additional, Hoppe, B.S., additional, Habermann, T.M., additional, Thanarajasingam, G., additional, Johnston, P., additional, Inwards, D.J., additional, Bennani, N., additional, Peterson, J.L., additional, Stish, B.J., additional, Rule, W.G., additional, Ansell, S.M., additional, and Lester, S.C., additional

Published
2022
Full Text
View/download PDF

5. Comprehensive Salvage Radiotherapy for Limited Relapsed B-Cell Non-Hodgkin Lymphoma Following CD19 Chimeric Antigen Receptor T-Cell Therapy

Author

Saifi, O., primary, Breen, W., additional, Lester, S.C., additional, Rule, W.G., additional, Stish, B.J., additional, Rosenthal, A., additional, Munoz, J., additional, Lin, Y., additional, Bennani, N., additional, Paludo, J., additional, Khurana, A., additional, Bisneto, J. Villasboas, additional, Johnston, P., additional, Ansell, S.M., additional, Iqbal, M., additional, Moustafa, M. Alhaj, additional, Murthy, H.S., additional, Kharfan-Dabaja, M., additional, Hoppe, B.S., additional, and Peterson, J.L., additional

Published
2022
Full Text
View/download PDF

6. Bridging Radiotherapy for Patients with Limited (

Author

Saifi, O., Breen, W., Lester, S.C., Rule, W.G., Stish, B.J., Rosenthal, A., Munoz, J., Lin, Y., Johnston, P., Ansell, S.M., Paludo, J., Khurana, A., Bisneto, J. Villasboas, Wang, Y., Iqbal, M., Moustafa, M. Alhaj, Murthy, H.S., Kharfan-Dabaja, M., Hoppe, B.S., and Peterson, J.L.

Published
2024
Full Text
View/download PDF

7. Metabolic Kinetics of Non-Hodgkin Lymphoma Prior to CAR-T Infusion: Prognostic Factors and Risk Stratification

Author

Breen, W., primary, Hathcock, M., additional, Young, J.R., additional, Stish, B.J., additional, Kowalchuk, R.O., additional, Bansal, R., additional, Khurana, A., additional, Bennani, N., additional, Paludo, J., additional, Bisneto, J. Villasboas, additional, Wang, Y., additional, Ansell, S.M., additional, Peterson, J.L., additional, Johnston, P., additional, Lin, Y., additional, and Lester, S.C., additional

Published
2021
Full Text
View/download PDF

9. Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.

Author

Hawkes E.A., Phillips T., Budde L.E., Santoro A., Saba N.S., Roncolato F., Gregory G.P., Verhoef G., Offner F., Quero C., Radford J., Giannopoulos K., Stevens D., Thall A., Huang B., Laird A.D., Sandner R., Ansell S.M., Hawkes E.A., Phillips T., Budde L.E., Santoro A., Saba N.S., Roncolato F., Gregory G.P., Verhoef G., Offner F., Quero C., Radford J., Giannopoulos K., Stevens D., Thall A., Huang B., Laird A.D., Sandner R., and Ansell S.M.

Abstract

Background: Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis despite the availability of multiple treatment options. Preliminary evidence suggests that DLBCL may be responsive to programmed death ligand 1 (PD-L1)/programmed death 1 inhibitors. Objective(s): The JAVELIN DLBCL study was conducted to assess whether a combination of agents could augment and sustain the antitumor immunity of avelumab, an anti-PD-L1 antibody, in R/R DLBCL. Method(s): This was a multicenter, randomized, open-label, parallel-arm study with a phase Ib and a phase III component. Reported here are the results from the phase Ib study, wherein 29 adult patients with DLBCL were randomized 1:1:1 to receive avelumab in combination with utomilumab (an immunoglobulin G2 4-1BB agonist) and rituximab (arm A), avelumab in combination with utomilumab and azacitidine (arm B), or avelumab in combination with bendamustine and rituximab (arm C). The primary endpoints were dose-limiting toxicities and objective response as assessed by the investigator per Lugano Response Classification criteria. Result(s): Of the seven patients in arm A, one (14.3%) experienced two grade 3 dose-limiting toxicities (herpes zoster and ophthalmic herpes zoster); no dose-limiting toxicities were reported in arms B or C. No new safety concerns emerged for avelumab. One partial response was reported in arm A, three complete responses in arm C, and no responses in arm B. Given the insufficient antitumor activity in arms A and B and the infeasibility of expanding arm C, the study was discontinued before initiation of the phase III component. Conclusion(s): The low level of clinical activity suggests that PD-L1 inhibitor activity may be limited in R/R DLBCL. ClinicalTrials.gov Identifier: NCT02951156.Copyright © 2021, The Author(s).

Published
2021

10. Progression risk stratification of asymptomatic Waldenström macroglobulinemia

Author

Bustoros, M. Sklavenitis-Pistofidis, R. Kapoor, P. Liu, C.-J. Kastritis, E. Zanwar, S. Fell, G. Abeykoon, J.P. Hornburg, K. Neuse, C.J. Marinac, C.R. Liu, D. Soiffer, J. Gavriatopoulou, M. Boehner, C. Cappuccio, J.M. Dumke, H. Reyes, K. Soiffer, R.J. Kyle, R.A. Treon, S.P. Castillo, J.J. Dimopoulos, M.A. Ansell, S.M. Trippa, L. Ghobrial, I.M.

Abstract

BACKGROUND Waldenström macroglobulinemia (WM) is preceded by asymptomatic WM (AWM), for which the risk of progression to overt disease is not well defined. METHODS We studied 439 patients with AWM, who were diagnosed and observed at Dana-Farber Cancer Institute between 1992 and 2014. RESULTS During the 23-year study period, with a median follow-up of 7.8 years, 317 patients progressed to symptomatic WM (72%). Immunoglobulin M 4,500 mg/dL or greater, bone marrow lymphoplasmacytic infiltration 70% or greater, b2-microglobulin 4.0 mg/dL or greater, and albumin 3.5 g/dL or less were all identified as independent predictors of disease progression. To assess progression risk in patients with AWM, we trained and cross-validated a proportional hazards model using bone marrow infiltration, immunoglobulin M, albumin, and beta-2 microglobulin values as continuous measures. The model divided the cohort into three distinct risk groups: a high-risk group with a median time to progression (TTP) of 1.8 years, an intermediate-risk group with a median TTP of 4.8 years, and a low-risk group with a median TTP of 9.3 years. We validated this model in two external cohorts, demonstrating robustness and generalizability. For clinical applicability, we made the model available as a Web page application (www.awmrisk.com). By combining two cohorts, we were powered to identify wild type MYD88 as an independent predictor of progression (hazard ratio, 2.7). CONCLUSION This classification system is positioned to inform patient monitoring and care and, for the first time to our knowledge, to identify patients with high-risk AWM who may need closer follow-up or benefit from early intervention. © 2019 by American Society of Clinical Oncology

Published
2019

11. Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes

Author

Din, L., Sheikh, M., Kosaraju, N., Smedby, K.E., Bernatsky, S., Berndt, S.I., Skibola, C.F., Nieters, A., McKay, J.D., Cocco, P., Maynadié, M., Foretová, L., Staines, A., Mack, T.M., de Sanjosé, S., Vyse, T.J., Padyukov, L., Monnereau, A., Arslan, A.A., Moore, A., Brooks-Wilson, A.R., Glimelius, B., Birmann, B.M., Link, B.K., Stewart, C., Vajdic, C.M., Haioun, C., Magnani, C., Conti, D.V., Cox, D.G., Casabonne, D., Albanes, D., Kane, E., Roman, E., Muzi, G., Salles, G., Giles, G.G., Adami, H.-O., Ghesquières, H., De Vivo, I., Clavel, J., Cerhan, J.R., Spinelli, J.J., Vijai, J., Curtin, K., Costenbader, K.H., Onel, K., Offit, K., Teras, L.R., Morton, L., Conde, L., Miligi, L., Melbye, M., Ennas, M.G., Liebow, M., Purdue, M.P., Glenn, M., Southey, M.C., Din, M., Rothman, N., Camp, N.J., Wong Doo, N., Becker, N., Pradhan, N., Bracci, P.M., Boffetta, P., Vineis, P., Brennan, P., Kraft, P., Lan, Q., Severson, R.K., Vermeulen, R.C.H., Milne, R.L., Kaaks, R., Travis, R.C., Weinstein, S.J., Chanock, S.J., Ansell, S.M., Slager, S.L., Zheng, T., Benavente, Y., Taub, Z., Madireddy, L., Gourraud, P.-A., Oksenberg, J.R., Cozen, W., Hjalgrim, H., Khankhanian, P., Din, L., Sheikh, M., Kosaraju, N., Smedby, K.E., Bernatsky, S., Berndt, S.I., Skibola, C.F., Nieters, A., McKay, J.D., Cocco, P., Maynadié, M., Foretová, L., Staines, A., Mack, T.M., de Sanjosé, S., Vyse, T.J., Padyukov, L., Monnereau, A., Arslan, A.A., Moore, A., Brooks-Wilson, A.R., Glimelius, B., Birmann, B.M., Link, B.K., Stewart, C., Vajdic, C.M., Haioun, C., Magnani, C., Conti, D.V., Cox, D.G., Casabonne, D., Albanes, D., Kane, E., Roman, E., Muzi, G., Salles, G., Giles, G.G., Adami, H.-O., Ghesquières, H., De Vivo, I., Clavel, J., Cerhan, J.R., Spinelli, J.J., Vijai, J., Curtin, K., Costenbader, K.H., Onel, K., Offit, K., Teras, L.R., Morton, L., Conde, L., Miligi, L., Melbye, M., Ennas, M.G., Liebow, M., Purdue, M.P., Glenn, M., Southey, M.C., Din, M., Rothman, N., Camp, N.J., Wong Doo, N., Becker, N., Pradhan, N., Bracci, P.M., Boffetta, P., Vineis, P., Brennan, P., Kraft, P., Lan, Q., Severson, R.K., Vermeulen, R.C.H., Milne, R.L., Kaaks, R., Travis, R.C., Weinstein, S.J., Chanock, S.J., Ansell, S.M., Slager, S.L., Zheng, T., Benavente, Y., Taub, Z., Madireddy, L., Gourraud, P.-A., Oksenberg, J.R., Cozen, W., Hjalgrim, H., and Khankhanian, P.

Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.

Published
2019

13. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC

Author

Radford, J., primary, Connors, J.M., additional, Younes, A., additional, Gallamini, A., additional, Ansell, S.M., additional, Kim, W.S., additional, Cheong, J., additional, Flinn, I., additional, Kalakonda, N., additional, Kaminski, M., additional, Pettengell, R., additional, Onsum, M., additional, Josephson, N., additional, Kuroda, S., additional, Liu, R., additional, Miao, H., additional, Gautam, A., additional, Trepicchio, W.L., additional, and Sureda, A., additional

Published
2019
Full Text
View/download PDF

14. OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY

Author

Maurer, M.J., primary, Jakopsen, L.H., additional, Habermann, T.M., additional, Nowakowski, G.S., additional, Ansell, S.M., additional, Thompson, C.A., additional, Brown, P.D., additional, Jørgensen, J.M., additional, Frederiksen, H., additional, Syrbu, S., additional, Feldman, A.L., additional, Novak, A.J., additional, Rimsza, L.M., additional, Cerhan, J.R., additional, El-Galaly, T.C., additional, and Link, B.K., additional

Published
2019
Full Text
View/download PDF

16. INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

Author

Ansell, S.M., primary, Bartlett, N.L., additional, Chen, R.W., additional, Herrera, A., additional, Domingo-Domenech, E., additional, Mehta, A., additional, Forero-Torres, A., additional, Garcia-Sanz, R., additional, Armand, P., additional, Devata, S., additional, Rodriguez Izquierdo, A., additional, Lossos, I.S., additional, Reeder, C.B., additional, Sher, T., additional, Choe-Juliak, C., additional, Prier, K., additional, Schwarz, S.E., additional, Strassz, A., additional, and Alland, L., additional

Published
2019
Full Text
View/download PDF

17. Exploring Host Germline Genetics to Help Identify Patients with Early Stage Lymphoma Who Might Benefit From the Addition of Radiation Therapy

Author

Lester, S.C., primary, Taparra, K., additional, Routman, D.M., additional, Maurer, M.J., additional, Ansell, S.M., additional, Feldman, A.L., additional, Link, B.K., additional, Stish, B.J., additional, Martenson, J.A., additional, Slager, S.L., additional, Stafford, S.L., additional, Habermann, T.M., additional, and Cerhan, J.R., additional

Published
2018
Full Text
View/download PDF

18. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

Leblond, V. Kastritis, E. Advani, R. Ansell, S.M. Buske, C. Castillo, J.J. García-Sanz, R. Gertz, M. Kimby, E. Kyriakou, C. Merlini, G. Minnema, M.C. Morel, P. Morra, E. Rummel, M. Wechalekar, A. Patterson, C.J. Treon, S.P. Dimopoulos, M.A.

Abstract

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM. © 2016 by The American Society of Hematology.

Published
2016

21. INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

Author

Herrera, A.F., primary, Moskowitz, A.J., additional, Bartlett, N.L., additional, Vose, J.M., additional, Ramchandren, R., additional, Feldman, T.A., additional, Lacasce, A.S., additional, Ansell, S.M., additional, Moskowitz, C.H., additional, Fenton, K., additional, Ogden, C., additional, Taft, D., additional, Zhang, Q., additional, Kato, K., additional, Campbell, M., additional, and Advani, R.H., additional

Published
2017
Full Text
View/download PDF

22. Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop

Author

Owen, R.G. Kyle, R.A. Stone, M.J. Rawstron, A.C. Leblond, V. Merlini, G. Garcia-Sanz, R. Ocio, E.M. Morra, E. Morel, P. Anderson, K.C. Patterson, C.J. Munshi, N.C. Tedeschi, A. Joshua, D.E. Kastritis, E. Terpos, E. Ghobrial, I.M. Leleu, X. Gertz, M.A. Ansell, S.M. Morice, W.G. Kimby, E. Treon, S.P.

Abstract

This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M (IgM) reduction with different treatment modalities and the apparent discrepancy between IgM and bone marrow/tissue response noted with some regimens. Planned sequential bone marrow assessments are encouraged in clinical trials. © 2012 Blackwell Publishing Ltd.

Published
2013

23. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

Author

Cozen, W., Timofeeva, M.N., Li, D., Diepstra, A., Hazelett, D., Delahaye-Sourdeix, M., Edlund, C.K., Franke, L., Rostgaard, K., Berg, D.J. Van Den, Cortessis, V.K., Smedby, K.E., Glaser, S.L., Westra, H.J., Robison, L.L., Mack, T.M., Ghesquieres, H., Hwang, A.E., Nieters, A., Sanjose, S. de, Lightfoot, T., Becker, N., Maynadie, M., Foretova, L., Roman, E., Benavente, Y., Rand, K.A., Nathwani, B.N., Glimelius, B., Staines, A., Boffetta, P., Link, B.K., Kiemeney, B., Ansell, S.M., Bhatia, S., Strong, L.C., Galan, P., Vatten, L., Habermann, T.M., Duell, E.J., Lake, A., Veenstra, R.N., Visser, L de, Liu, Y., Urayama, K.Y., Montgomery, D., Gaborieau, V., Weiss, L.M., Byrnes, G., Lathrop, M., Cocco, P., Best, T., Skol, A.D., Adami, H.O., Melbye, M., Cerhan, J.R., Gallagher, A., Taylor, G.M., Slager, S.L., Brennan, P., Coetzee, G.A., Conti, D.V., Onel, K., Jarrett, R.F., Hjalgrim, H., Berg, A. van den, McKay, J.D., Cozen, W., Timofeeva, M.N., Li, D., Diepstra, A., Hazelett, D., Delahaye-Sourdeix, M., Edlund, C.K., Franke, L., Rostgaard, K., Berg, D.J. Van Den, Cortessis, V.K., Smedby, K.E., Glaser, S.L., Westra, H.J., Robison, L.L., Mack, T.M., Ghesquieres, H., Hwang, A.E., Nieters, A., Sanjose, S. de, Lightfoot, T., Becker, N., Maynadie, M., Foretova, L., Roman, E., Benavente, Y., Rand, K.A., Nathwani, B.N., Glimelius, B., Staines, A., Boffetta, P., Link, B.K., Kiemeney, B., Ansell, S.M., Bhatia, S., Strong, L.C., Galan, P., Vatten, L., Habermann, T.M., Duell, E.J., Lake, A., Veenstra, R.N., Visser, L de, Liu, Y., Urayama, K.Y., Montgomery, D., Gaborieau, V., Weiss, L.M., Byrnes, G., Lathrop, M., Cocco, P., Best, T., Skol, A.D., Adami, H.O., Melbye, M., Cerhan, J.R., Gallagher, A., Taylor, G.M., Slager, S.L., Brennan, P., Coetzee, G.A., Conti, D.V., Onel, K., Jarrett, R.F., Hjalgrim, H., Berg, A. van den, and McKay, J.D.

Abstract

Contains fulltext : 137763.pdf (publisher's version ) (Open Access), Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI)=0.76-0.86, Pcombined=3.5 x 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regulator of B- and T-cell lineage commitment known to be involved in HL pathogenesis. This meta-analysis also notes associations between previously published loci at 2p16, 5q31, 6p31, 8q24 and 10p14 and HL subtypes. We conclude that our data suggest a link between the 19p13.3 locus, including TCF3, and HL risk.

Published
2014

25. Bowel perforation in intestinal lymphoma: incidence and clinical features

Author

Vaidya, R., primary, Habermann, T.M., additional, Donohue, J.H., additional, Ristow, K.M., additional, Maurer, M.J., additional, Macon, W.R., additional, Colgan, J.P., additional, Inwards, D.J., additional, Ansell, S.M., additional, Porrata, L.F., additional, Micallef, I.N., additional, Johnston, P.B., additional, Markovic, S.N., additional, Thompson, C.A., additional, Nowakowski, G.S., additional, and Witzig, T.E., additional

Published
2013
Full Text
View/download PDF

26. Incidence of Cardiac Arrhythmias During Autologous Peripheral Blood Stem Cell Transplantation

Author

Singla, A., primary, Hogan, W.H., additional, Ansell, S.M., additional, Buadi, F.K., additional, Dingli, D., additional, Dispenzieri, A., additional, Gastineau, D.A., additional, Gertz, M.A., additional, Hayman, S.R., additional, Inwards, D.J., additional, Johnston, P.B., additional, Lacy, M.Q., additional, Litzow, M.R., additional, Micallef, I.N., additional, Porrata, L.F., additional, and Kumar, S.K., additional

Published
2012
Full Text
View/download PDF

27. A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization

Author

Micallef, I.N., primary, Sinha, S., additional, Gastineau, D.A., additional, Wolf, R., additional, Inwards, D.J., additional, Gertz, M.A., additional, Hayman, S.R., additional, Hogan, W.J., additional, Johnston, P.B., additional, Lacy, M.Q., additional, Ansell, S.M., additional, Buadi, F., additional, Dingli, D., additional, Dispenzieri, A., additional, Litzow, M.R., additional, Porrata, L.F., additional, Winters, J.L., additional, and Kumar, S., additional

Published
2011
Full Text
View/download PDF

28. Azithromycin For Bronchiolitis Obliterans Following Allogeneic Hematopoietic Stem Cell Transplantation

Author

Maciuleviciute, E., primary, Burzynski, J.A., additional, Wolf, R.C., additional, Ansell, S.M., additional, Buadi, F.K., additional, Dingli, D., additional, Dispenzieri, A., additional, Gastineau, D.A., additional, Gertz, M.A., additional, Inwards, D.J., additional, Johnston, P.B., additional, Kumar, S., additional, Lacy, M.Q., additional, Litzow, M.R., additional, Micallef, I.N.M., additional, Porrata, L.E., additional, and Hogan, W.J., additional

Published
2010
Full Text
View/download PDF

29. A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization

Author

Micallef, I.N., primary, Inwards, D.J., additional, Dispenzieri, A., additional, Gastineau, D.A., additional, Gertz, M.A., additional, Hayman, S., additional, Hogan, W.J., additional, Johnston, P.B., additional, Kumar, S., additional, Lacy, M., additional, Litzow, M.R., additional, Porrata, L.E., additional, Buadi, F., additional, Ansell, S.M., additional, Dingli, D., additional, Wolf, R., additional, Miceli, T., additional, and Winters, J.L., additional

Published
2010
Full Text
View/download PDF

31. Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation

Author

Howle, E.L., primary, Wolf, R.C., additional, Burzynski, J.A., additional, Gastineau, D.A., additional, Lacy, M.Q., additional, Gertz, M.A., additional, Dispenzieri, A., additional, Kumar, S., additional, Dingli, D., additional, Buadi, F., additional, Inwards, D.J., additional, Ansell, S.M., additional, Micallef, I.N.M., additional, Johnston, P.B., additional, Porrata, L.F., additional, Elliott, M.A., additional, Hogan, W.J., additional, and Litzow, M.R., additional

Published
2009
Full Text
View/download PDF

32. Peripheral Blood CD34 Count Can Predict Successful Progenitor Cell Mobilization in Poor Mobiliziers Treated With Plerixafor and G-CSF

Author

Micallef, I.N., primary, Maurer, M., additional, Ansell, S.M., additional, Buadi, F., additional, Dispenzieri, A., additional, Gastineau, D.A., additional, Gertz, M.A., additional, Hayman, S.R., additional, Hogan, W.J., additional, Inwards, D.J., additional, Johnston, P.B., additional, Kumar, S., additional, Lacy, M.Q., additional, Litzow, M.R., additional, Porrata, L.F., additional, Winters, J.L., additional, Marzolf, M., additional, Shaw, T., additional, and Calandra, G., additional

Published
2009
Full Text
View/download PDF

35. 87: Peripheral Blood Stem Cell Transplant for POEMS Syndrome is Associated with High Rates of Engraftment Syndrome

Author

Dispenzieri, A., primary, Lacy, M.Q., additional, Hayman, S.R., additional, Kumar, S.K., additional, Buadi, F., additional, Dingli, D., additional, Litzow, M.R., additional, Gastineau, D.A., additional, Inwards, D.J., additional, Elliott, M.A., additional, Micallef, I.N., additional, Ansell, S.M., additional, Hogan, W.J., additional, Porrata, L.F., additional, Johnston, P.B., additional, Afessa, B., additional, Bryce, A., additional, Kyle, R.A., additional, and Gertz, M.A., additional

Published
2008
Full Text
View/download PDF

37. 255: Rescue Mobilization of Hematopoietic Progenitor Cells with AMD3100 + G-CSF is Successful in Patients Who Previously Failed Mobilization

Author

Micallef, I.N.M., primary, Ansell, S.M., additional, Buadi, F., additional, Dispenzieri, A., additional, Elliott, M.A., additional, Gertz, M.A., additional, Hayman, S.R., additional, Hogan, W.J., additional, Inwards, D.J., additional, Gastineau, D.A., additional, Johnston, P.B., additional, Kumar, S., additional, Lacy, M.Q., additional, Porrata, L.F., additional, Marzolf, M., additional, Shaw, T., additional, Winters, J.L., additional, Calandra, G., additional, and Litzow, M.R., additional

Published
2008
Full Text
View/download PDF

38. The IPI Predicts Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: A Report of the University of Iowa/Mayo Clinic SPORE

Author

Habermann, Thomas M., primary, Link, B.K., additional, Maurer, M.J., additional, Wooldridge, J.E., additional, Geyer, S.M., additional, Macon, W.R., additional, Allmer, C., additional, Ansell, S.M., additional, Witzig, T.E., additional, Weiner, G.J., additional, and Cerhan, J.R., additional

Published
2007
Full Text
View/download PDF

45. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma.

Author

Ansell, S.M., Arendt, B.K., Grote, D.M., Jelinek, D.F., Novak, A.J., Wellik, L.E., Remstein, E.D., Bennett, C.F., and Fielding, A.

Subjects
*PROTEINS, *APOPTOSIS, *LYMPHOMAS, *GENE expression, *CELL division, *XENOGRAFTS
Abstract

Survivin is a member of the inhibitor of apoptosis protein (IAP) family and functions both as an apoptosis inhibitor and a regulator of cell division. Survivin overexpression is common in many human tumors and correlates with survival in large cell non-Hodgkin's lymphoma. To evaluate this molecule as a potential therapeutic target in large-cell lymphoma, we evaluated the effect of survivin inhibition both in vitro and in vivo. Using an antisense oligonucleotide (ASO) approach, cell growth was significantly inhibited in the DoHH2, RL and HT lymphoma cell lines. In a lymphoma xenograft model, the development of tumors as well as the growth of established tumors was inhibited in the survivin ASO-treated mice compared to controls. To assess the efficacy of the survivin ASO in combination with other biological agents, we combined the survivin ASO with an anti-CD20 monoclonal antibody, rituximab. The effect of survivin ASO and rituximab in combination was additive in vitro. In vivo, however, suppression of tumor growth with the combination was not significantly superior to controls. We conclude that inhibition of survivin expression is an attractive therapeutic strategy in aggressive non-Hodgkin's lymphomas, and that combining survivin ASO with rituximab may enhance the efficacy of this approach.Leukemia (2004) 18, 616-623. doi:10.1038/sj.leu.2403281 Published online 29 January 2004 [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results